Key result
Anticoagulation achieves ~46% complete resolution for bioprosthetic valve thrombosis but carries notable bleeding risk.
Why the study?
Clinically significant thrombosis of surgical and transcatheter biological valves is increasingly recognised, yet most reviews have concentrated on subclinical leaflet thrombosis after transcatheter aortic valve implantation rather than clinical bioprosthetic valve thrombosis in the aortic or mitral position.
Does anticoagulation or reintervention improve haemodynamic outcomes and resolution in patients with clinical bioprosthetic valve thrombosis in the aortic or mitral position?
Does anticoagulation or reintervention improve haemodynamic outcomes and resolution in patients with clinical bioprosthetic valve thrombosis in the aortic or mitral position?
Answers are grounded in this paper and cite their sources.
This narrative review highlights that vitamin K antagonists are the primary treatment for haemodynamically stable clinical bioprosthetic valve thrombosis despite a lack of randomized trials, though recurrence and bleeding risks require individualized extended therapy.
Clinically significant thrombosis of surgical and transcatheter biological valves is increasingly recognised, yet most reviews have concentrated on subclinical leaflet thrombosis after transcatheter aortic valve implantation. This narrative review examines treatment and outcomes after diagnosis of clinical bioprosthetic valve thrombosis in the aortic or mitral position, keeping asymptomatic hypoattenuated leaflet thickening separate. The evidence consists of 17 observational cohorts and case series, several of which overlap, include right-sided valves or use treatment response as part of the diagnosis; no randomised treatment trial has been reported. After anticoagulation, mainly with vitamin K antagonists, most studies reported haemodynamic improvement in most patients assessed, but endpoints and denominators varied; in one transcatheter registry, complete resolution was reported in 12 of 26 patients (46%), a figure that included two patients who were not anticoagulated. Recovery often took several months. Recurrence and bleeding estimates come mainly from one mixed-valve cohort that included right-sided prostheses: thrombosis recurred in 23% of initial responders, and major bleeding occurred in 12% of treated patients versus 2% of matched controls, an observational difference that cannot be attributed wholly to anticoagulation. Evidence for thrombolysis, redo surgery and transcatheter reintervention is limited to small series and case reports. The evidence supports confirming suspected thrombosis with transoesophageal echocardiography or four-dimensional computed tomography, starting a vitamin K antagonist in haemodynamically stable patients, referring unstable patients or those with persistent obstruction for a Heart Team decision, and individualising extended anticoagulation against bleeding risk. Direct oral anticoagulants are not established for clinical thrombosis, and the optimal duration of treatment is unknown.
No takes yet. Share an insight, caveat, or question.
Sunil Kumar Ohri (2026) conducted a review in Clinical bioprosthetic valve thrombosis in the aortic or mitral position. Anticoagulation (mainly vitamin K antagonists) vs. Matched controls (in one bleeding cohort) was evaluated on Complete resolution of thrombosis and major bleeding across reviewed cohorts. Anticoagulation (mainly VKAs) for clinical bioprosthetic valve thrombosis showed 46% complete resolution in one registry, with 23% recurrence and major bleeding in another cohort.
Synapse has enriched 10 related papers. Consider them for comparative context: